Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.26 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 14.04 | Oscillator | Buy |
| Williams %R (14) | -72.07 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.12 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 40.12 (+DI 21.4 / -DI 38.4) | Trend | Strong Sell |
Current price $0.411
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 23, 26 | BTIG | maintain |
| EMA 20 | 0.54 | MA | Strong Sell |
| SMA 20 | 0.56 | MA | Strong Sell |
| EMA 50 | 0.71 | MA | Strong Sell |
| SMA 50 | 0.77 | MA | Strong Sell |
| SMA 200 | 1.04 | MA | Strong Sell |
| Buy |
| Buy |
| Aug 27, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Aug 17, 26 | BTIG | maintain | Buy | Buy |
| Jun 8, 26 | Ascendiant Capital | maintain | Buy | Buy |
| May 15, 26 | Maxim Group | maintain | Buy | Buy |
| May 15, 26 | BTIG | maintain | Buy | Buy |
| Apr 9, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Mar 30, 26 | BTIG | maintain | Buy | Buy |
| Mar 26, 26 | Needham | maintain | Buy | Buy |
Stock news · updated daily
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on October 21, 2026, for shares of its newly designated Series C Convertible Preferred Stock (the "Series C Preferred Stock") to existing long-term shareholders.
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 Coordination and Maintenance Committee NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.
Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify Barrett's Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage decision and expands relationships with commercial payers, the Department of Veterans Affairs and health systems.
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare draft local coverage determination, or LCD.
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Thursday, August 13, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.06 | -0.06 | Miss -5.9% | $1.47M |
| May 14, 2026 | -0.05 | -0.07 | Miss -40.0% | $1.26M |
| Mar 25, 2026 | -0.07 | -0.10 | Miss -42.9% | $1.50M |
| Nov 12, 2025 | -0.06 | -0.10 | Miss -66.7% | $1.21M |
| Aug 13, 2025 | -0.09 | -0.10 | Miss -11.1% | $1.16M |
| May 14, 2025 | -0.09 | -0.16 | Miss -77.8% | $828.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | LUCD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.9x | -2.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.5x | EPS est. -0.27 | Elevated |
| Price / Book | 6.9x | -0.4x | Discount |
| Price / Sales | 14.4x | 115.0x | Discount |
| EV / EBITDA | -1.4x | -1.9x | Discount |
| Return on equity | -404.3% | — | Weak |
| Gross margin | -25.8% | -255.1% | Below hist. |
| Debt / Equity | 2.28 | -0.04 | Levered |
| Piotroski / Altman Z | 3/9 | Z -13.57 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 20, 26 | Matheis Dennis | director | P-Purchase | 245,000 @ $1.00 | $245.3K |
| Mar 23, 26 |
| Lee Victoria Tou-Ho |
| officer: Chief Medical Officer |
| 100,000 @ $1.25 |
| $125.0K |
| Mar 23, 26 | Lee Victoria Tou-Ho | officer: Chief Medical Officer | 0 | — |
| Feb 20, 26 | Aklog Lishan | director, officer: Chief Executive Officer | A-Award | 2,170,000 | — |
| Feb 20, 26 | Matheis Dennis | director | A-Award | 123,000 | — |
| Feb 20, 26 | White Debra | director | A-Award | 123,000 | — |
| Feb 20, 26 | Sparks Ronald M | director | A-Award | 123,000 | — |
| Feb 20, 26 | Sokolov Jacque J | director | A-Award | 123,000 | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 22, 2026 | 2026-10-22 16:34:57 | View |
| 8-K | Oct 16, 2026 | 2026-10-16 16:30:28 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 09:06:43 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 08:23:31 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:30:49 | View |
| 8-K | Jun 24, 2026 | 2026-06-24 17:00:31 | View |
| 4 | May 21, 2026 | 2026-05-21 16:20:02 | View |
| 8-K | May 14, 2026 | 2026-05-14 08:05:15 | View |
| 10-Q | May 13, 2026 | 2026-05-13 16:31:36 | View |
| DEFA14A | Apr 30, 2026 | 2026-04-30 17:03:10 | View |
Proxy statement (DEF 14A) disclosures